Intranasal Covid-19 vaccine production commences at Pune’s Serum Institute of India
Intranasal vaccine for Covid-19 virus SARS-CoV-2 is not under any clinical trial currently, but Serum Institute of India has started production of an intranasal vaccine candidate, informed Union Health Minister Dr. Harsh Vardhan on Monday. Various Covid-19 vaccine candidates are currently under human trials in India.
Dr. Harsh Vardhan said, “Flumist nasal spray is a vaccine that is sprayed into the nose to help protest against influenza; it is not a Covid-19 vaccine. At present in India, there is no intranasal Covid vaccine which is under clinical trials. However, Serum Institute of India has begun manufacturing Codagenix CDX 005, which is an intranasal live attenuated vaccine candidate for Sars-Cov-2.”
The phase 1 trials will take place in the US in St. Louis University’s vaccine and treatment evaluation unit, on getting regulatory approval, Bharat Biotech will pursue further stages of clinical trials in IndiaDr. Harsh Vardhan
“Pre-clinical animal studies have already been completed and Codagenix expects to initiate a phase 1 clinical first in humans trial in the United Kingdom by the end of 2020. Further, Serum India plans to undertake clinical developments of this vaccine candidate in India,” he added.
As a part of the sixth episode of Sunday Samvaad, the Minister was responding to the questions on his social media accounts. He relayed that India’s Bharat Biotech has also signed an agreement with Washington University School of Medicine. Through this trials will be conducted to produce and market an intranasal vaccine for Covid-19.
“The phase 1 trials will take place in the US in St. Louis University’s vaccine and treatment evaluation unit, on getting regulatory approval, Bharat Biotech will pursue further stages of clinical trials in India,” he said.
Dr. Harsh Vardhan said that Bharat Biotech’s vaccine candidate was being tested on people between 18 and 55 years in phase 1, and for phase 2, it was extended to include participants of ages between 12 and 65 years.